Clal Biotech (CBI) Stock Statistics & Valuation Metrics
Total Valuation
Clal Biotech has a market cap or net worth of ILA 35.92M. The enterprise value is ILA 61.33T.
- Market Cap
- ILA 35.92M
- Enterprise Value
- ILA 61.33T
Share Statistics
Clal Biotech has 156,846,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 156,846,200
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Clal Biotech’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -44.02%.
- Return on Equity (ROE)
- -0.66
- Return on Assets (ROA)
- -0.32
- Return on Invested Capital (ROIC)
- -44.02%
- Return on Capital Employed (ROCE)
- -0.72
- Revenue Per Employee
- 6,900.826
- Profits Per Employee
- -110.07K
- Employee Count
- 121
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Clal Biotech is -3.95. Clal Biotech’s PEG ratio is -0.03.
- PE Ratio
- -3.95
- PS Ratio
- 28.13
- PB Ratio
- 2.64
- Price to FCF
- -10.91
- Price to Operating Cash Flow
- -10.24
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Clal Biotech had revenue of 835.00K and earned -13.32M in profits. Earnings per share was -0.08.
- Revenue
- 835.00K
- Gross Profit
- 364.00K
- Operating Income
- -18.41M
- Pretax Income
- -20.17M
- Net Income
- -13.32M
- EBITDA
- -19.83M
- Earnings Per Share (EPS)
- -0.08
Cash Flow
In the last 12 months, operating cash flow was -3.29M and capital expenditures 0, giving a free cash flow of -3.29M billion.
- Operating Cash Flow
- -3.29M
- Free Cash Flow
- -3.29M
- Free Cash Flow per Share
- -0.02
Dividends & Yields
Clal Biotech pays an annual dividend of ILA 22.37, resulting in a dividend yield of ―
- Dividend Per Share
- ILA 22.37
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.17%
- Earnings Yield
- -26.27%
Stock Price Statistics
- Beta
- 0.38
- 52-Week Price Change
- -27.53%
- 50-Day Moving Average
- 23.62
- 200-Day Moving Average
- 28.07
- Relative Strength Index (RSI)
- 47.55
- Average Volume (3m)
- 111.05K
Important Dates
Clal Biotech upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- ―
- Next Earnings Date
- ―
- Ex-Dividend Date
- Mar 29, 2021
Financial Position
Clal Biotech as a current ratio of 0.14, with Debt / Equity ratio of 87.92%
- Current Ratio
- 0.14
- Quick Ratio
- 0.14
- Debt to Market Cap
- 0.34
- Net Debt to EBITDA
- -0.81
- Interest Coverage Ratio
- -149.69
Taxes
In the past 12 months, Clal Biotech has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Clal Biotech EV to EBITDA ratio is -19.90, with an EV/FCF ratio of -15.37.
- EV to Sales
- 39.61
- EV to EBITDA
- -19.90
- EV to Free Cash Flow
- -15.37
- EV to Operating Cash Flow
- -15.37
Balance Sheet
Clal Biotech has ILA 1.59M in cash and marketable securities with ILA 16.26M in debt, giving a net cash position of -ILA 14.67M billion.
- Cash & Marketable Securities
- ILA 1.59M
- Total Debt
- ILA 16.26M
- Net Cash
- -ILA 14.67M
- Net Cash Per Share
- -ILA 0.09
- Tangible Book Value Per Share
- ILA 0.10
Margins
Gross margin is 100.00%, with operating margin of -194.91%, and net profit margin of -693.74%.
- Gross Margin
- 100.00%
- Operating Margin
- -194.91%
- Pretax Margin
- -1199.37%
- Net Profit Margin
- -693.74%
- EBITDA Margin
- -199.06%
- EBIT Margin
- -211.82%
Analyst Forecast
The average price target for Clal Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- -149.11%
- EPS Growth Forecast
- 71.79%